KOREA WHO
-
-
Chairman of Vivozon Pharmaceutical
Lee Du-hyeon
Pain-Focused R&D Nears World’s First Non-Opioid Analgesic
-
Last Updated on Oct 29, 2025
-
Chairman of Vivozon Pharmaceutical
Copy Url : https://www.koreawho.com/profile/LeeDuhyeon- Life Summary
Lee Du-hyeon is the Chairman of Vivozon Pharmaceutical and also serves as the CEO of Vivozon.
He focuses on new drug research and development, particularly in the field of innovative analgesic development.
He was born in January 1961.
After completing his Ph.D. program in Biopsychology at Korea University, he conducted research on pain and neuroscience at the University of Texas in the United States.
He then participated in analgesic development for more than a decade at global pharmaceutical companies such as Amgen, Johnson & Johnson PRD, and Eli Lilly.
In 2008, he founded Vivozon.
He developed “Enapraju” (ingredient name: Opiranserin), the world’s first non-narcotic, non-anti-inflammatory analgesic.
#Vivozon #LeeDuhyeon #pharmaceutical #painkiller #biotechnology #Amgen #JohnsonandJohnson #EliLilly #nonopioid #drugdevelopment #innovation
He focuses on new drug research and development, particularly in the field of innovative analgesic development.
He was born in January 1961.
After completing his Ph.D. program in Biopsychology at Korea University, he conducted research on pain and neuroscience at the University of Texas in the United States.
He then participated in analgesic development for more than a decade at global pharmaceutical companies such as Amgen, Johnson & Johnson PRD, and Eli Lilly.
In 2008, he founded Vivozon.
He developed “Enapraju” (ingredient name: Opiranserin), the world’s first non-narcotic, non-anti-inflammatory analgesic.
#Vivozon #LeeDuhyeon #pharmaceutical #painkiller #biotechnology #Amgen #JohnsonandJohnson #EliLilly #nonopioid #drugdevelopment #innovation
- Life Summary
- Career Highlights & Challenges
- · Vivozon Pharmaceutical’s Governance Structure
- · Falling Sales and Continued Losses Undermine Profitability
- · Enapra High-Concentration Injection Begins U.S. Clinical Drug Production
- · VVZ-2471 Targets Pain and Addiction, IND Submitted for U.S. Phase 1 Trial
- · Vivozon Pharmaceutical Signs Partnership with Daiichi Sankyo Korea for ‘Enapraju’
- · First Shipment of ‘Enapraju’ Arrives in Korea
- · ‘Enapraju’ Wins Korea New Drug Development Award
- · Vivozon Pharmaceutical Obtains Marketing Authorization for Korea’s 38th New Drug
- · Vivozon Partners with Boryung for Domestic Commercialization of Enapraju
- · Vivozon Expands Pipeline with Three New Innovative Drugs
- · Pursuing a Backdoor Listing through Acquisition of IniST Biopharma
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- - Investor Sentiment Freezes After Rights Offering Announcement
- - FSC Refers Vivozon Pharmaceutical Executives to Prosecutors for Insider Trading Allegations
- - National Tax Service Refers Vivozon Pharmaceutical to Prosecutors After Tax Evasion Probe
- - Vivozon Pharmaceutical Faces Administrative Sanctions for Noncompliance with Manufacturing Standards
- - Vivozon Pharmaceutical Fined by Fair Trade Commission for Rebate Violations
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos